Evelien Moorkens

911 total citations
17 papers, 360 citations indexed

About

Evelien Moorkens is a scholar working on Economics and Econometrics, Immunology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Evelien Moorkens has authored 17 papers receiving a total of 360 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Economics and Econometrics, 16 papers in Immunology and 5 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Evelien Moorkens's work include Biosimilars and Bioanalytical Methods (16 papers), Pharmaceutical Economics and Policy (15 papers) and Health Systems, Economic Evaluations, Quality of Life (8 papers). Evelien Moorkens is often cited by papers focused on Biosimilars and Bioanalytical Methods (16 papers), Pharmaceutical Economics and Policy (15 papers) and Health Systems, Economic Evaluations, Quality of Life (8 papers). Evelien Moorkens collaborates with scholars based in Belgium, Netherlands and United Kingdom. Evelien Moorkens's co-authors include Arnold G. Vulto, Isabelle Huys, Steven Simoens, Paul Declerck, Brian Godman, Hye-Young Kwon, SeungJin Bae, Eleonora Allocati, Gisbert Selke and Martin Schulz and has published in prestigious journals such as SHILAP Revista de lepidopterología, Frontiers in Pharmacology and Value in Health.

In The Last Decade

Evelien Moorkens

16 papers receiving 346 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Evelien Moorkens Belgium 10 258 218 73 66 51 17 360
Hillel P. Cohen United States 8 426 1.7× 257 1.2× 156 2.1× 33 0.5× 45 0.9× 15 496
Hans C. Ebbers Netherlands 14 514 2.0× 288 1.3× 196 2.7× 60 0.9× 89 1.7× 31 645
Martin Schiestl Austria 12 353 1.4× 109 0.5× 90 1.2× 159 2.4× 161 3.2× 19 472
Niklas Ekman Finland 6 320 1.2× 146 0.7× 105 1.4× 20 0.3× 56 1.1× 9 357
Elena Wolff‐Holz Germany 10 576 2.2× 293 1.3× 225 3.1× 51 0.8× 95 1.9× 19 681
Ena Singh United States 7 235 0.9× 119 0.5× 65 0.9× 43 0.7× 47 0.9× 7 323
Leon van Aerts Netherlands 3 361 1.4× 175 0.8× 126 1.7× 21 0.3× 62 1.2× 3 437
Liese Barbier Belgium 9 288 1.1× 224 1.0× 119 1.6× 13 0.2× 41 0.8× 36 362
Basant Sharma United States 9 118 0.5× 16 0.1× 28 0.4× 176 2.7× 102 2.0× 11 301
M. Saar Estonia 6 43 0.2× 136 0.6× 20 0.3× 26 0.4× 43 0.8× 11 279

Countries citing papers authored by Evelien Moorkens

Since Specialization
Citations

This map shows the geographic impact of Evelien Moorkens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evelien Moorkens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evelien Moorkens more than expected).

Fields of papers citing papers by Evelien Moorkens

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evelien Moorkens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evelien Moorkens. The network helps show where Evelien Moorkens may publish in the future.

Co-authorship network of co-authors of Evelien Moorkens

This figure shows the co-authorship network connecting the top 25 collaborators of Evelien Moorkens. A scholar is included among the top collaborators of Evelien Moorkens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evelien Moorkens. Evelien Moorkens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Moorkens, Evelien, Dalia Dawoud, András Inotai, et al.. (2023). A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: An ISPOR Special Interest Group Report. Value in Health. 26(8). 1137–1144. 6 indexed citations
2.
Simoens, Steven, Liese Barbier, Rosanne Janssens, et al.. (2022). How to balance valuable innovation with affordable access to medicines in Belgium?. Frontiers in Pharmacology. 13. 960701–960701. 7 indexed citations
3.
4.
Moorkens, Evelien, Arnold G. Vulto, & Isabelle Huys. (2020). Biosimilars in Belgium: a proposal for a more competitive market. Acta Clinica Belgica. 76(6). 441–452. 16 indexed citations
5.
Moorkens, Evelien, Arnold G. Vulto, Martin Schulz, et al.. (2020). Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany. Pharmaceuticals. 13(10). 324–324. 22 indexed citations
6.
Moorkens, Evelien, et al.. (2020). Economic evaluation of biosimilars for reimbursement purposes – what, when, how?. SHILAP Revista de lepidopterología. 8(1). 1739509–1739509. 9 indexed citations
7.
Moorkens, Evelien, Arnold G. Vulto, & Isabelle Huys. (2020). An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?. mAbs. 12(1). 1743517–1743517. 32 indexed citations
8.
Kwon, Hye-Young, et al.. (2020). Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?. Frontiers in Pharmacology. 11. 970–970. 43 indexed citations
9.
Godman, Brian, Eleonora Allocati, Evelien Moorkens, & Hye-Young Kwon. (2020). Can local policies on biosimilars optimize the use of freed resources – experiences from Italy. Generics and Biosimilars Initiative Journal. 9(4). 183–187. 5 indexed citations
10.
11.
12.
Godman, Brian, Eleonora Allocati, & Evelien Moorkens. (2019). Ever-changing landscape of biosimilars in Canada; findings and implications from a global perspective. Generics and Biosimilars Initiative Journal. 8(3). 93–97. 9 indexed citations
13.
Moorkens, Evelien, Arnold G. Vulto, & Isabelle Huys. (2018). Biosimilars ∙ Regulatory Frameworks for Marketing Authorisation of Biosimilars: Where Do We Go From Here?. Lirias (KU Leuven). 2(3). 149–154. 5 indexed citations
14.
Moorkens, Evelien, et al.. (2017). The Design of Economic Evaluation and Budget Impact Analysis Of Biosimilars: A Qualitative Study. Value in Health. 20(9). A737–A737. 1 indexed citations
15.
Moorkens, Evelien, et al.. (2017). The Market of Biopharmaceutical Medicines: A Snapshot of a Diverse Industrial Landscape. Frontiers in Pharmacology. 8. 314–314. 73 indexed citations
16.
Moorkens, Evelien, et al.. (2016). Market Uptake Models Of Biosimilars And Off-Patent Biological Medicines. Value in Health. 19(7). A452–A452.
17.
Moorkens, Evelien, et al.. (2016). Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies. Frontiers in Pharmacology. 7. 193–193. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hillel P. Cohen Breakdown of academic impact, for papers by Hans C. Ebbers Breakdown of academic impact, for papers by Martin Schiestl Breakdown of academic impact, for papers by Niklas Ekman Breakdown of academic impact, for papers by Elena Wolff‐Holz Breakdown of academic impact, for papers by Ena Singh Breakdown of academic impact, for papers by Leon van Aerts Breakdown of academic impact, for papers by Liese Barbier Breakdown of academic impact, for papers by Basant Sharma Breakdown of academic impact, for papers by M. Saar
Rankless by CCL
2026